Months af­ter launch­ing with lofty goal, Flag­ship start­up stream­lines ops, chops head­count

Even by Flag­ship Pi­o­neer­ing’s stan­dards, the stat­ed goal at Vesal­ius Ther­a­peu­tics — un­veiled at its launch this March — was ex­ceed­ing­ly am­bi­tious. Armed with $75 mil­lion in Se­ries A fund­ing, the start­up was out to “rev­o­lu­tion­ize the treat­ment of the dis­eases that dri­ve nine­ty per­cent of hu­man ill­ness.” It would, as CEO Christo­pher Austin ex­plained, de­ploy cut­ting-edge tech­nol­o­gy to look for un­der­ly­ing caus­es for a dizzy­ing ar­ray of com­mon dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER